The New York Entrepreneur

[stock-market-ticker symbols="AAPL;MSFT;GOOG;HPQ;^SPX;^DJI;LSE:BAG" stockExchange="NYSENasdaq" width="100%" palette="financial-dark"]
Menu
Earnings

Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar

Read Time:6 Second

The success of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
0 0
Previous post ‘He does not manage his own bills’: My brother is about to take Social Security. Should we put his inheritance from our father’s estate into an annuity?
Next post Restaurant Brands revenue tops estimates, fueled by Tim Hortons

More Stories